Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis

Breast Cancer Research and Treatment

Volumn 149, Issue 2, 2015, Pages 403-415

  Li, Yanchun ^a   Reader, Jocelyn C ^a   Ma, Xinrong ^a   Kundu, Namita ^a,b   Kochel, Tyler ^a   Fulton, Amy M ^a,b,c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Baltimore Veterans Administration   (United States)

Author keywords

Breast cancer metastasis; Cancer stem cells; Chemokine; Chemokine receptor CXCR3 isoforms

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 A; CHEMOKINE RECEPTOR CXCR3 B; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; BREAST METASTASIS; CANCER STEM CELL; CELL FUNCTION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; ALTERNATIVE RNA SPLICING; BREAST TUMOR; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL10; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTEIN ISOFORMS; RECEPTORS, CXCR3; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84925498870     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3229-7     Document Type: Article

References (25)

1. Fulton A (ed) (2009) Chemokine receptors in cancer. Springer Publisher, Dordrecht
2. Billottet C, Quemener C, Bikfalvi A (2013) CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 1836:287–295
3. Li Y, Fulton AM (2012) CXCR3/CXCL3 axis: friend or foe? In: Ben-Baruch A (ed) The inflammatory milieu of tumors: cytokines and chemokines that affect tumor growth and metastasis. Bentham Science Publishers, United Arab Emirates, pp 88–98
4. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A (2004) The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 92(1–2):171–178
5. Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A (2009) CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3):490–498
6. Hilborn E, Sivik T, Fornander T, Stal O, Nordenskjold B, Jansson A (2014) CXC ligand 10 and CXC receptor 3 status can predict tamoxifen treatment response in breast cancer patients. Breast Cancer Res Treat 145:73–82
7. Walser T, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson M, Medina J, Collins T, Fulton A (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66:7701–7707
8. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S (2006) Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 66(19):9509–9518
9. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O’Malley FP, Ohashi PS, Andrulis I (2013) Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res 19:336–346
10. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L et al (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197(11):1537–1549
11. Robledo MM, Bartolomé RA, Longo N, Rodríguez-Frade JM, Mellado M, Longo I, van Muijen GNP, Sánchez-Mateos P, Teixidó J (2001) Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 276(48):45098–45105
12. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM (2007) Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26(32):4679–4688
13. Wu Z, Dhir R, Wells A (2012) Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 11:3
14. Utsumi T, Suyama T, Imamura Y, Fuse M, Sakamoto S, Nihei N, Ueda T, Suzuki H, Seki N, Ichikawa T (2014) The association of CXCR3 and renal cell carcinoma metastasis. J Urol 192:567
15. Petrai I, Rombouts K, Lasagni L, Annunziato F, Cosmi L, Romanelli RG et al (2008) Activation of p38MAPK mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 40(9):1764–1774
16. Balan M, Pal S (2014) A novel CXCR3-B chemokine receptor induced growth inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem 289:3126–3137
17. Shin SY, Nam J-S, Lim Y, Lee YH (2010) TNFα-exposed bone marrow derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 285:30731–30740
18. Kundu S, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, Fulton A (2014) Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 143:19–31
19. Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, Burger M (2009) Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer 100:1949–1956
20. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107(1):43–52
21. Yi T, Zhai B, Yu Y, Kiyotsugu Y, Raschle T, Etzkorn M, Seo H-C et al (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci 111:E2182–E2190
22. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120:485–497
23. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
24. Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, Barsheshet Y et al (2014) CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 124:2009–2022
25. Patsialou A, Wang Y, Pignatelli J, Chen X, Entenberg D, Oktay M, Condeelis JS (2014) Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells. Oncogene. doi:10.1038/onc.2014.226